Empirical Antitubercular Drug Extended 9-Month Regimen

Introduction to the Regimen

The World Health Organization recommends a 9-month antitubercular drug regimen consisting of an intensive phase with at least five effective drugs for 4 months, followed by a 5-month continuation phase with fluoroquinolone, clofazimine, ethambutol, and pyrazinamide, for patients with drug-resistant tuberculosis 1

The intensive phase should include at least five effective TB medicines to reduce the risk of treatment failure and development of further drug resistance, according to the American Thoracic Society 2
The recommended 9-month all-oral regimen consists of bedaquiline, fluoroquinolone, clofazimine, ethambutol, high-dose isoniazid, and either ethionamide or linezolid, as suggested by the International Journal of Infectious Diseases 1

After completing the intensive phase, treatment continues with fluoroquinolone, clofazimine, ethambutol, and pyrazinamide, as recommended by the World Health Organization 1

The 9-month regimen is the preferred treatment option over longer regimens for patients without previous exposure to second-line treatment, including bedaquiline, according to the International Journal of Infectious Diseases 1
For patients with extensive pulmonary disease, severe extrapulmonary TB, CNS, miliary, or osteoarticular TB, longer treatment (18-20 months) is still recommended, as suggested by the American Journal of Respiratory and Critical Care Medicine 2

When choosing a fluoroquinolone, levofloxacin is often preferred over moxifloxacin due to moxifloxacin's higher potential for cardiotoxicity, although both have similar efficacy, according to the International Journal of Infectious Diseases 1
If pyrazinamide cannot be used, an additional agent from WHO groups C or D can be added to strengthen the regimen, as recommended by the European Respiratory Journal 3

Directly observed therapy (DOT) is recommended to ensure adherence to the regimen, according to the American Journal of Respiratory and Critical Care Medicine 2
Regular monitoring of bacteriology (sputum smear and culture) is essential to assess treatment response, as suggested by the American Journal of Respiratory and Critical Care Medicine 2
Drug toxicity monitoring should be performed according to international recommendations to limit the probability of losing an effective drug due to adverse events, as recommended by the European Respiratory Journal 3

The 9-month regimen should not be used in cases with confirmed resistance to fluoroquinolones, previous exposure to second-line drugs for more than 1 month, intolerance to any of the medicines in the regimen, or unavailability of any medicine in the regimen, according to the International Journal of Infectious Diseases 1
Treatment decisions for drug-resistant TB should ideally be made by a team of experts rather than individual physicians to minimize errors and share expertise, as suggested by the European Respiratory Journal 3